Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN versus SITAVIG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN versus SITAVIG.
GABAPENTIN vs SITAVIG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin is a structural analog of GABA but does not bind to GABA receptors. It binds to the α2δ subunit of voltage-gated calcium channels, reducing calcium influx and decreasing the release of excitatory neurotransmitters.
Sitavig (acyclovir) is a synthetic nucleoside analogue that inhibits viral DNA replication. It is phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, leading to chain termination.
Initial dose: 300 mg orally once daily on day 1, 300 mg twice daily on day 2, then 300 mg three times daily on day 3; titrate as needed up to 1800-3600 mg/day in three divided doses. Maximum single dose: 1200 mg. Dose adjustments for renal impairment should be made based on creatinine clearance.
Topical: Apply one 50 mg buccal tablet to the upper gum above the incisor region once daily for 14 days.
None Documented
None Documented
Clinical Note
moderateGabapentin + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluticasone propionate."
Clinical Note
moderateGabapentin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Gabapentin."
Clinical Note
moderateGabapentin + Fluconazole
"The serum concentration of Fluconazole can be increased when it is combined with Gabapentin."
Clinical Note
moderateGabapentin + Clemastine
5-7 hours (normal renal function); prolonged to 50-140 hours in end-stage renal disease; half-life independent of dose due to linear kinetics.
Terminal elimination half-life is approximately 20 hours in adults with normal renal function. In patients with renal impairment (CrCl <30 mL/min), half-life increases to up to 40 hours, necessitating dose adjustment.
Renal: 76-81% unchanged in urine; biliary/fecal: <5% as metabolites; remainder (10-20%) as minor metabolites via urine.
Primarily renal; approximately 80% of the dose is excreted unchanged in urine within 24 hours. Minor fecal excretion (less than 10%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Gabapentin is combined with Clemastine."